Lumida
/AVD
⌘K
American Vanguard Corp

American Vanguard Corp

AVD
$2.61USD↓-2.97%-0.08 today

MARKET CAP

74.7M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2
$6

AI Summary

Stalk
TrimMedium

AVD remains in an early Stage 1 consolidation after a steep decline, with intermediate resistance forming at flattening EMAs and a declining 200 DMA. Medium-term bias stays bearish on the lower-high structure, while short-term timing is neutral. Defer selling into the $2.90–3.00 zone on rejections at the 9/20 EMA or 50 SMA. A decisive break below the EMA zone would trigger accelerated bearish risk and invalidate the current setup.

  • ↑Net sales $124M (+7% YoY), domestic crop sales up 17%.
  • ↑Adjusted EBITDA rose 245% YoY to $10.3M, driven by cost control and margin mix.
  • ↓Total debt increased to $267M from $166M, straining financial flexibility.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

American Vanguard Corporation (NYSE: AVD) is a leading player in the agricultural chemicals sector, specializing in the development and marketing of crop protection products such as herbicides, fungicides, and insecticides. The company is currently transforming its operations to improve efficiency and navigate challenges in the agricultural landscape, focusing on enhancing productivity and sustainability while addressing competitive pressures from generic products and fluctuating commodity prices.

Bull says

  • ↑Net sales $124M (+7% YoY), domestic crop sales up 17%.
  • ↑Adjusted EBITDA rose 245% YoY to $10.3M, driven by cost control and margin mix.
  • ↑Operating expenses fell to 26.7% of sales from 27.9%, boosting efficiency.
  • ↑Pipeline to launch 50 new products by 2030, targeting +$100M revenue.
  • ↑U.S. manufacturing footprint offers resilience amid tariff-driven pricing shifts.
  • ↑Strong operational framework and positive analyst revisions support fundamentals.

Bear says

  • ↓Total debt increased to $267M from $166M, straining financial flexibility.
  • ↓Generics intensify pricing competition, weighing on margins and profit sustainability.
  • ↓Liquidity pressures may limit cash flow management and growth investments.
  • ↓Commodity volatility and geopolitical tensions threaten volume growth.
  • ↓Weak profitability indicators and negative momentum damp investor sentiment.
  • ↓Elevated short interest reflects market skepticism on near-term outlook.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-05-2026neutral

Transcript signals

Bull points

  • Medtem sales were up 14% in the quarter versus last year. This is our largest single product and continues to be well respected in the market.
  • Thiamet sales were also up 17%, and this can be attributed to the increase in peanut acreage that was planted this year.
  • We expect this hard work should begin to materialize in the upcoming quarters.

Bear points

  • our first quarter 2025 revenue was $116 million, a decrease of 14% as compared to the first quarter of 2024. The primary reasons for the decrease were, first, as Dak just mentioned, destocking continued in the quarter. Secondly, the absence of a voluntarily cancelled herbicide from our product portfolio. Third, weakness in the Mexican agave market. And finally, a drought in parts of Australia impacting sales of certain products.
  • Gross profit margin declined to 26% during the quarter compared to 31% last year. This decline in gross profit margin was primarily related to a weaker pricing environment and to a lesser degree lower volumes.
  • It is likely that debt will trend higher during the second quarter, which is normal for the company's annual cycle.
Read full transcript analysis ›